Literature DB >> 7594721

Divergent human papillomavirus type 16 variants are serologically cross-reactive.

G Cheng1, J P Icenogle, R Kirnbauer, N L Hubbert, M E St Louis, C Han, E I Svare, S K Kjaer, D R Lowy, J T Schiller.   

Abstract

It is not known whether DNA sequence variants of human papillomavirus type 16 (HPV-16) are distinct serotypes. To examine this question, the reactivities of women's sera from Zaire (n = 97) and Denmark (n = 123) were compared in IgG-specific ELISAs based on virus-like particles (VLPs) composed of the L1 major capsid protein derived from an HPV-16 variant common in central Africa (Z-1194) or one common in northern Europe (114K). These L1s differ in seven amino acids. There was a strong correlation between reactivity in the two assays for both sets of sera (correlation coefficients, 0.73 and 0.85 for Zairian and Danish sera, respectively). In only 1 serum was there evidence for a specific reaction to one but not the other VLP variant. The results support the conclusion that the virions of strains Z-1194 and 114K are serologically cross-reactive.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7594721     DOI: 10.1093/infdis/172.6.1584

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  14 in total

1.  Characterization of a human papillomavirus type 16 variant-dependent neutralizing epitope.

Authors:  R B Roden; A Armstrong; P Haderer; N D Christensen; N L Hubbert; D R Lowy; J T Schiller; R Kirnbauer
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

2.  Human papillomavirus type 16 sequence variation in cervical cancers: a worldwide perspective.

Authors:  T Yamada; M M Manos; J Peto; C E Greer; N Munoz; F X Bosch; C M Wheeler
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

Review 3.  The role of vaccines in the control of STDs: HPV vaccines.

Authors:  I H Frazer
Journal:  Genitourin Med       Date:  1996-12

4.  Naturally Occurring Capsid Protein Variants of Human Papillomavirus Genotype 31 Represent a Single L1 Serotype.

Authors:  Sara L Bissett; Anna Godi; Maxime J J Fleury; Antoine Touze; Clementina Cocuzza; Simon Beddows
Journal:  J Virol       Date:  2015-05-20       Impact factor: 5.103

5.  In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype.

Authors:  R B Roden; H L Greenstone; R Kirnbauer; F P Booy; J Jessie; D R Lowy; J T Schiller
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

6.  Diversifying selection in human papillomavirus type 16 lineages based on complete genome analyses.

Authors:  Zigui Chen; Masanori Terai; Leiping Fu; Rolando Herrero; Rob DeSalle; Robert D Burk
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

7.  Papillomavirus capsid mutation to escape dendritic cell-dependent innate immunity in cervical cancer.

Authors:  Rongcun Yang; Cosette M Wheeler; Xiaojiang Chen; Satoshi Uematsu; Kiyoshi Takeda; Shizuo Akira; Diana V Pastrana; Raphael P Viscidi; Richard B S Roden
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

8.  Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition.

Authors:  R B Roden; N L Hubbert; R Kirnbauer; N D Christensen; D R Lowy; J T Schiller
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

9.  Serological relationship between cutaneous human papillomavirus types 5, 8 and 92.

Authors:  Alessandra Handisurya; Ratish Gambhira; Christina Schellenbacher; Saeed Shafti-Keramat; Ola Forslund; Michel Favre; Reinhard Kirnbauer
Journal:  J Gen Virol       Date:  2009-01       Impact factor: 3.891

10.  The L1 major capsid protein of human papillomavirus type 16 variants affects yield of virus-like particles produced in an insect cell expression system.

Authors:  A Touze; S El Mehdaoui; P Y Sizaret; C Mougin; N Muñoz; P Coursaget
Journal:  J Clin Microbiol       Date:  1998-07       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.